February 22, 2017 / 7:35 PM / 2 years ago

Genmab's Darzalex could achieve peak annual sales of $9 billion - CEO

Genmab Chief Executive Jan van de Winkel poses for a photograph in London, Britain, October 13, 2016. REUTERS/Ben Hirschler

COPENHAGEN (Reuters) - Danish biotech drugmaker Genmab’s (GEN.CO) Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson (JNJ.N), has the potential to achieve annual peak annual sales as high as $13 billion (10.46 billion pounds), its chief executive told Reuters.

“It could work in other blood cancers as well as in solid tumours. So that means $13 billion potential if it would work in all the indications, Jan van de Winkel said on Wednesday.

He acknowledged that $13 billion would be the most rosy scenario but said that Darzalex could “definitely” achieve more than $9 billion.

Genmab expects sales of Darzalex to surpass $1 billion this year, the company said on Wednesday.

Reporting by Stine Jacobsen; Editing by David Goodman

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below